Phase 2 N=22 Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer
Head and Neck Carcinoma
Primary: Overall Response Rate — 22.7 percentage
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=48 Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck
Recurrent Head and Neck Cancer · Carcinoma, Squamous Cell of Head and Neck
Primary: Progression Free Survival — 7.9 months
Phase 3 N=882 A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)
Recurrent Head and Neck Cancer · Metastatic Head and Neck Cancer
Primary: Pembro Combo vs Control: Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review…
Phase 2 N=123 A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck
Squamous Cell Carcinoma of Head and Neck
Primary: Percentage of Participants With Confirmed Objective Response, as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST…
Phase 2 N=425 Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Head and Neck Cancer
Primary: Objective Response Rate (ORR) as Determined by Blinded Independent Central Review (BIRC) - Platinum Refractory Subgroup — 13.2; 18.3 percentage of participants — p=0.2897
Phase 2 N=172 Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
Head and Neck Squamous Cell Carcinoma
Primary: Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in All Participants — 16.4 Percentage of participants — p=<0.001
Phase 2 N=69 A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Head and Neck Neoplasms
Primary: Progression-Free Survival (PFS) — 5.1 months
Phase 3 N=89 Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Head and Neck Cancer
Primary: Objective Response Rate (ORR) of Pembrolizumab + Epacadostat, Pembrolizumab Monotherapy and the EXTREME Regimen — 31.4; 21.1; 34.3 percentage of participants
Phase 2 N=112 Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck
Primary: Objective Response Rate (ORR) — 16.2; 14.6; 18.9; 10.0 % of participants
Phase 2 N=66 A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Head and Neck Neoplasms
Primary: Progression Free Survival (PFS) — 4.4 months
Phase 3 N=361 Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)
Squamous Cell Carcinoma of the Head and Neck
Primary: Overall Survival (OS) — 7.49; 5.06 Months — p=0.0101
Phase 2 N=20 Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
Squamous Cell Carcinoma of the Head and Neck
Primary: Probability of Objective Response (OR) - Selected Treatment — 0 percentage of patients
Phase 2 N=55 A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)
Squamous Cell Carcinoma of Head and Neck
Primary: Best Percentage Change in Tumour Size — -7.88; -12.93 Percentage change from baseline — p=0.7008
Phase 2 N=95 Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
Squamous Cell Carcinoma of the Oropharynx · Squamous Cell Carcinoma of the Larynx · Squamous Cell Carcinoma of the Oral Cavity
Primary: Phase I: Maximum Tolerated Dose — 500 mg/m^2
Phase 3 N=495 Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Head and Neck Squamous Cell Cancer
Primary: Initial Overall Survival (OS) for All Participants — 8.4; 7.1 Months — p=0.03160
Phase 2 N=67 Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
Cancer of Head and Neck · Head and Neck Cancer · Neoplasms, Head and Neck
Primary: Locoregional Recurrence Rates in Cohorts 1 and 2 — 2; 2 Participants
Phase 1 N=36 Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)
Carcinoma of the Head and Neck
Primary: Number of Participants With a Dose Limiting Toxicity (DLT) — 1 Participants
Phase 3 N=947 Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Head and Neck Cancer
Primary: Overall Survival (OS) in Participants With Programmed Death-Ligand 1 (PD-L1) With a Combined Positive Score (CPS) ≥20 — 17.58; 14.59 Months — p=0.0469
Phase 2 N=69 Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer
Head and Neck Neoplasms
Primary: Percentage of Participants With Objective Response (OR) of Complete Response (CR) or Partial Response (PR) — 12.5 Percentage of participants
Phase 2 N=50 Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck
Squamous Cell Cancers of the Head and Neck
Primary: Tumor Shrinkage — 2; 9; 36 Participants
Phase 2 N=267 Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck
Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck
Primary: Objective Response Rate at 6 Months — 7.7; 9.2; 1.6 % participants
Phase 1 N=59 Pembrolizumab in Combination With CRT for LA-SCCHN
Head and Neck Cancer · Squamous Cell Carcinoma · Oral Cavity Cancer
Primary: Adverse Events Will be Assessed and Graded Using CTCAE 4.0. Occurrences With Max Grade and Percentage/Number of Participants Affected by AEs Will be Provided. — 57…
Phase 2 N=18 The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck
Squamous Cell Carcinoma of the Head and Neck
Primary: Number of Subjects With Dose Limiting Toxicities — 0 Participants
Phase 2 N=52 PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
Cancer · Carcinoma · Head and Neck Cancer
Primary: Objective Response Rate — 3.9 percentage of participants
Phase 2 N=26 Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN
Head and Neck Squamous Cell Carcinoma · Head and Neck Cancer · Head and Neck Cancer Metastatic
Primary: Safety as Measured by Number of Participants With Drug-related Adverse Events — 19; 2 Participants
Phase 2 N=50 Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
Head and Neck Squamous Cell Carcinoma · Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma · Recurrent Nasopharynx Carcinoma
Primary: Incidence of Toxicity Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 — 1; 1; 0; 1 Participants
Phase 2 N=29 Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin
Head and Neck Cancer
Primary: 20 Week Progression Free Survival Rate — 0.90 proportion of participants
Phase 2 N=7 Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
Head and Neck Cancer · Head and Neck Squamous Cell Carcinoma · Head and Neck Carcinoma
Primary: Rate of Dose Limiting Toxicity (DLT) — 1 Participants
Phase 2 N=374 Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)
Squamous Cell Carcinoma of Head and Neck
Primary: Overall Survival (OS) — 8.4; 11.3 Months — p=0.9963
Phase 2 N=12 A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)
Squamous Cell Carcinoma of the Head and Neck
Primary: Percentage of Participants With Pathologic Complete Response (pCR) as Determined by Local Pathologic Review — 16.7; 50.0 percentage of participants